Discipline of Surgery, University of Adelaide, Adelaide, South Australia, Australia.
Discipline of Surgery, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Br J Surg. 2018 Sep;105(10):1262-1272. doi: 10.1002/bjs.10923. Epub 2018 Jul 12.
Preoperative immunonutrition has been proposed to reduce the duration of hospital stay and infective complications following major elective surgery in patients with gastrointestinal malignancy. A multicentre 2 × 2 factorial RCT was conducted to determine the impact of preoperative and postoperative immunonutrition versus standard nutrition in patients with oesophageal cancer.
Patients were randomized before oesophagectomy to immunonutrition (IMPACT ) versus standard isocaloric/isonitrogenous nutrition, then further randomized after operation to immunonutrition versus standard nutrition. Clinical and quality-of-life outcomes were assessed at 14 and 42 days after operation on an intention-to-treat basis. The primary outcome was the occurrence of infective complications. Secondary outcomes were other complications, duration of hospital stay, mortality, nutritional and quality-of-life outcomes (EuroQol EQ-5D-3 L™, European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-OES18). Patients and investigators were blinded until the completion of data analysis.
Some 278 patients from 11 Australian sites were randomized; two were excluded and data from 276 were analysed. The incidence of infective complications was similar for all groups (37 per cent in perioperative standard nutrition group, 51 per cent in perioperative immunonutrition group, 34 per cent in preoperative immunonutrition group and 40 per cent in postoperative immunonutrition group; P = 0·187). There were no significant differences in any other clinical or quality-of-life outcomes.
Use of immunonutrition before and/or after surgery provided no benefit over standard nutrition in patients undergoing oesophagectomy. Registration number: ACTRN12611000178943 ( https://www.anzctr.org.au).
术前免疫营养已被提议用于减少胃肠道恶性肿瘤患者接受大择期手术后的住院时间和感染并发症。一项多中心 2×2 析因 RCT 旨在确定术前和术后免疫营养与食管癌患者标准营养的影响。
在食管切除术之前,患者被随机分为免疫营养(IMPACT)与标准等热量/等氮营养,然后在手术后进一步随机分为免疫营养与标准营养。根据意向治疗原则,在术后 14 和 42 天评估临床和生活质量结局。主要结局是感染性并发症的发生。次要结局是其他并发症、住院时间、死亡率、营养和生活质量结局(EuroQol EQ-5D-3L™、欧洲癌症研究与治疗组织(EORTC)QLQ-C30 和 EORTC QLQ-OES18)。患者和研究人员在完成数据分析之前保持盲法。
来自澳大利亚 11 个地点的 278 名患者被随机分组;2 名被排除,276 名患者的数据被分析。所有组的感染性并发症发生率相似(围手术期标准营养组为 37%,围手术期免疫营养组为 51%,术前免疫营养组为 34%,术后免疫营养组为 40%;P=0.187)。任何其他临床或生活质量结局均无显著差异。
在接受食管切除术的患者中,术前和/或术后使用免疫营养与标准营养相比没有益处。注册号:ACTRN12611000178943(https://www.anzctr.org.au)。